| +0.06 / +0.14%|
The 9 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 46.00, with a high estimate of 54.00 and a low estimate of 40.00. The median estimate represents a +8.82% increase from the last price of 42.27.
The current consensus among 10 polled investment analysts is to Buy stock in Haemonetics Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.